Armida D’Incecco
Agostino Gemelli University Polyclinic · 55 works · 2,768 citations · h-index 19
Top works
- A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study
- Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
- Association of Polymorphisms inAKT1andEGFRwith Clinical Outcome and Toxicity in Non–Small Cell Lung Cancer Patients Treated with Gefitinib
- Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients
- microRNA classifiers are powerful diagnostic/prognostic tools in ALK- , EGFR- , and KRAS -driven lung cancers
- Let-7g and miR-21 expression in non-small cell lung cancer: Correlation with clinicopathological and molecular features
- Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors
- Rare Mutations in Non-Small-Cell Lung Cancer
- Impact of ABCG2 Polymorphisms on the Clinical Outcome and Toxicity of Gefitinib in Non-Small-Cell Lung Cancer Patients
- The neuropilin 2 isoform NRP2b uniquely supports TGFβ-mediated progression in lung cancer
- Targeted therapy for NSCLC with driver mutations
- MicroRNA Signature in Metastatic Colorectal Cancer Patients Treated With Anti-EGFR Monoclonal Antibodies
- Chest wall reconstruction in benign and malignant tumors with non-rigid materials: An overview
- Targeting c-MET in the battle against advanced nonsmall-cell lung cancer
- Second-line Treatment for Non–Small-Cell Lung Cancer: One Size Does Not Fit All
- Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: results from the Pembro-real 5Y global registry
- Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)
- Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients